Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study

Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4. The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations. As a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.

NCT Number	NCT07651540
Lead Sponsor	Centre Hospitalier Universitaire de Saint Etienne
Conditions	Sensory Neuronopathy
Enrollment	70 participants
Start Date	2026-07-06
Primary Completion	2028-06-25 (estimated)
Study Completion	2028-06-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-10